T he prevalence of borderline personality disorder is 1% to 2% in the general population.
T he prevalence of borderline personality disorder is 1% to 2% in the general population. 1 Individuals with borderline personality disorder (BPD-I) report a wide range of symptoms such as mood instability, impulsivity, and difficulty concentrating and maintaining focus. In addition to this broad array of symptoms, BPD-I report severe sleep difficulties. 2 Although the sleep of BPD-I has been studied before, [2] [3] [4] [5] [6] [7] [8] [9] [10] little research has been aimed at quantifying the subjective sleep quality of these individuals and the severity of their sleep difficulties.
Only a handful of studies on BPD-I and their sleep have been published so far. [2] [3] [4] [5] [6] [7] [8] [9] [10] All of them, including the most recent, 2 have been aimed at characterizing the sleep of BPD-I by taking into account their personality peculiarities, which are numerous compared to controls, and comparing them with, for example, individuals with Axis-I diagnoses (e.g., severe depression) or controls who describe themselves as good sleepers. In earlier studies, shortened rapid eye movement (REM) latency 3, 4 and greater REM density 3, 5 were observed in BPD-I compared to controls. These results suggested that BPD-I shared common sleep and biological features with severe depression sufferers. Even when concomitant depression was controlled for, most studies have found either shortened REM latency or increased REM density. Furthermore, Philipsen et al. 2 recently observed greater delta power in the sleep NREM microstructure of BPD-I, even if participants had no history or symptoms of concomitant affective disorders. These authors did not, however, confirm previous polysomnographic depression-like observations in BPD-I. In addition, the effect of different medications on sleep has been rarely controlled for in previous studies; thus, even if BPD-I differ from controls, it is possible that medication further alters sleep architecture. Nonetheless, it appears that BPD-I show sleep PSG peculiarities. One might also suggest that besides depression or common features shared with other personality disorders (e.g., antisocial disorder), PSG results obtained with BPD-I might demonstrate the findings of a very heterogeneous group of bad sleepers. In that regard, Philipsen et al. 2 observed that BPD-I reported worse sleep quality than controls on the Pittsburgh Sleep Quality Index (PSQI). However, during laboratory recordings, BPD-I did not differ from GS on general clinical subjective sleep measures (total wake and sleep time, latency to sleep onset, and sleep efficiency), while still reporting a worse sleep quality. In the same study, a lower percentage of stage 2 was observed in BPD-I than in GS on the baseline night. Although these results are interesting, clinical sleep measures were computed on only one night. Furthermore, stage 2 reduction was obtained on only one night and by comparing the adaptation night with the baseline night. This observation might have only been linked to a first night effect artifact. It is possible that multiple recordings might offer different results. If Philipsen et al. 2 obtained subjective sleep reports, these authors did not discuss the implication of these results. It thus remains unknown if subjective sleep reports were concordant with objective reports or if clinical sleep measures were indicative of insomnia, stimulating development of the present study.
Signs of Insomnia in Borderline Personality
While about 30% of individuals in the general population report having a bad night of sleep occasionally, between 8% and 15% of individuals complain of chronic sleep difficulties.
11,12
According to Edinger et al., 13 psychophysiological (Psy-I) and paradoxical (Para-I) insomnia sufferers differ greatly regarding sleep (both objectively and subjectively). Subjective and objective comparisons between these 2 groups are still scarce in the literature. The main feature of Psy-I is that they display a great emphasis on sleep and reports often include an inability to initiate sleep when wanted, sleeping better away from home, intrusive thoughts at night (mind racing), somatic tension, and difficulty relaxing in bed. Conversely, Para-I severely overestimate their sleep difficulties. Marked differences between subjective and objective sleep, with laboratory findings of > 6.5 hours of sleep on PSG and sleep efficiency > 85% are observed. Reported "normal" nights are rare, and sleep diaries indicate sleepless nights and no naps. Similarly, BPD-I repeatedly report having sleepless nights and rarely being able to get a good night's sleep. These subjective reports thus resemble those reported by Para-I.
The first aim of the present study was thus to document subjective and objective sleep in BPD-I and to verify if these individuals suffer from chronic insomnia. This was accomplished by comparing subjective and objective sleep of BPD-I to the subjective and objective sleep of Psy-I, and Para-I. Subjective and objective measures of sleep were recorded and compared in these 3 groups of participants, then compared to the sleep characteristics of good sleeper controls. Our hypothesis was that the objective sleep of BDP-I would share common features with good sleepers while subjective reports would resemble those of Psy-I and Para-I.
MetHoDS

Participants
There were 57 adults who participated in the study, including 12 individuals suffering from borderline personality disorder (12 [9.9] ). Participants had a mean age of 36.4 years (SD = 9.5; range = 23 to 52 years). More than 96% of participants had a high school degree, 47% were single, and 61% held a full-time job. The mean duration of insomnia was 9.4 years (SD = 8.1) for psychophysiological insomnia sufferers and 13.8 years (SD = 9.7) for paradoxical insomnia sufferers.
Good SleeperS (GS)
Participants included in the GS group reported being satisfied with their sleep and (a) did not have subjective complaints of sleep difficulties, (b) did not meet diagnostic criteria for insomnia, and (c) did not use sleep-promoting medication. They also reported sleep efficiency ≥ 85% on the sleep diaries and no sleep difficulty of a higher level than "mild" on the Insomnia Severity Index (ISI; score < 8).
pSychophySioloGical inSomnia participantS (pSy-i)
The individuals suffering from chronic psychophysiological insomnia had to meet the following inclusion criteria: (a) presence of a subjective complaint of insomnia, defined as difficulty initiating (i.e., sleep onset latency > 30 min) and/or maintaining sleep (i.e., time awake after sleep onset > 30 min) present ≥ 4 nights per week; (b) insomnia duration ≥ 6 months; (c) insomnia or its perceived consequences causing marked distress or significant impairment of occupational or social functioning (e.g., problem of concentration); and (d) presence of a subjective complaint of at least one negative daytime consequence attributed to insomnia (e.g., fatigue, mood disturbances). These participants also corresponded to the criteria set forward by Edinger et al. 13 for psychophysiological insomnia.
paradoxical inSomnia participantS (para-i)
In addition to the above mentioned chronic primary insomnia criteria for Psy-I, paradoxical insomnia participants (a) had a total sleep time > 6.5 h and sleep efficacy > 85% on nocturnal polysomnography; (b) showed marked discrepancies between subjective (in-lab morning reports) and objective sleep measures (i.e., a difference ≥ 60 min for sleep latency or total sleep time, or a difference ≥ 15% between subjective and objective measures of sleep efficiency). These criteria are also in accordance with those suggested by Edinger et al. 13 and discrepancies between subjective and objective sleep parameters exceed those observed for psychophysiological insomnia sufferers. The following observation is also common in Para-I: complaint of severe sleep difficulties most of the time (sleepiness nights on sleep diaries being an indicator of difficulties), and the report of normal sleep is rare. We have established that the diagnosis for paradoxical insomnia is best confirmed following the first 2 nights of laboratory recordings, and this procedure is applied in the present study. ; (b) obtain a score ≥7 on the Diagnostic Interview for Borderline Revised (DIB-R); (c) have had the last episode of any other psychiatric lifetime diagnosis ≥ 6 months prior to the PSG investigation.
Exclusion criteria were: (a) presence of a significant current medical (e.g., cancer, diabetes) or neurological disorder (e.g., dementia, Parkinson disease) that compromises sleep; (b) presence of an Axis I disorder (such as major depression, general-ized anxiety disorder, bipolar, schizophrenia, and posttraumatic stress disorder); (c) alcohol abuse or drug dependence during the past year; (d) evidence of another sleep disorder such as sleep apnea (apnea-hypopnea index > 15) or periodic limb movements during sleep (myoclonic index with arousal >15); (e) a score ≥ 23 on the Beck Depression Inventory (BDI) 16 ; (f) use of psychotropic or other medications known to alter sleep (e.g., bronchodilators); and (g) use of a sleep-promoting agent (e.g., benzodiazepines). For participants with insomnia, criteria were consistent with those of the International Classification of Sleep Disorders (ICSD-2) 17 and the DSM-IV 15 for chronic and primary insomnia. 18 Participants who used a sleep-promoting medication on occasional basis (twice a week or less often) were enrolled in the study after a 2-week withdrawal period.
Recruiting, Screening and general Procedure
GS, Psy-I, and Para-I participants were recruited through newspaper advertisements. Following a telephone interview, eligible participants were mailed questionnaires aimed at evaluating the presence of psychological symptoms (BDI; Beck Anxiety Inventory, BAI), 16, 19 sleep (2 weeks of daily sleep diaries) as well as severity of sleep disturbances (ISI). 20 Upon receipt of questionnaires, prospective participants were invited for a clinical interview at the research center. Upon arrival, informed consent was obtained. The Structured Clinical Interview for DSM-IV (SCID-I and SCID-II) 21 and the Insomnia Diagnostic Interview (IDI) 20 were then administered to participants. BPD-I were recruited through advertisements at Centre de traitement Le Faubourg St-Jean, a clinic specialized in treating severe personality disorders, and which belongs to a psychiatric hospital in Quebec City (Institut Universitaire en Santé Mentale Robert-Giffard). Advertising indicated that prospective participants should not use any psychotropic medications and should present active symptoms of BPD. Recruitment was for participating in a study related to attention which included event-related potentials recorded during wake and sleep as well as neuropsychological testing. Advertisements were thus not focused on sleep. Prospective BPD-I were invited for a clinical interview at Le Faubourg St-Jean and informed consent was then obtained. The SCID-I, 21 the IDI, 20 and a clinical interview for BPD, the DIB-R, were administered. The Barratt Impulsiveness Scale (BIS), the Temperament and Character Inventory (TCI), the BDI, the BAI, a daily sleep diary, and the ISI were also completed.
All evaluations were conducted respectively by clinical psychologists (SG, GSJ, and SL) and a sleep specialist (CB). After the clinical evaluation, included participants were invited to undergo 3 consecutive nights of PSG recordings at the sleep laboratory. Each participant received an honorarium for his or her participation in the study.
Materials inSomnia diaGnoStic interview
The Insomnia Diagnostic Interview 20 is conducted in a semistructured format and assesses the presence of insomnia and potential contributing factors. It is designed to identify (a) the nature of the complaint, (b) the sleep-wake schedule, (c) insomnia severity, (d) daytime consequences, (e) the natural history of insomnia, (f) environmental factors, (g) medication use, (h) sleep hygiene factors, (i) the presence of other sleep disorders, (j) the patient's medical history and general health status, and (k) a functional analysis for antecedents, consequences, precipitating, and perpetuating factors.
Sleep diary
The sleep diary 20 is a daily journal used to assess subjective sleep quality. The various sleep-wake parameters derived for this study were sleep onset latency (SOL); wake after sleep onset (WASO); early morning awakening (EMA); frequency of awakenings (FNA); total wake time (TWT); total sleep time (TST); time in bed (TIB); and finally, sleep efficiency (SE), defined as the ratio of TST divided by TIB, expressed as a percentage. The sleep diary is usually completed upon arising each morning for a 2-week baseline period in order to provide a stable index of sleep complaints. In addition, our participants completed the sleep diary each morning upon awakening in the sleep laboratory. A mean was calculated for each of the derived variables.
inSomnia Severity index
The ISI 20 is a reliable and valid brief self-report instrument that yields a quantitative index of perceived insomnia severity. 22 The ISI comprises 7 items targeting the severity of sleep disturbances, the satisfaction relative to sleep, the degree of impairment of daytime functioning caused by the sleep disturbances, the noticeability of impairment attributed to the sleep problem as well as the degree of distress and concern related to the sleep problem. Each item is rated on a 5-point Likert scale, and the total score ranges from 0 to 28. A higher score reveals more severe insomnia. The ISI partly reflects the diagnostic criteria outlined in the DSM-IV. 15 diaGnoStic inventory for Borderline-reviSed
The DIB-R 23 is a semi-structured interview designed to assess borderline symptoms in four areas of functioning: affect, cognition, impulsivity, and interpersonal relationships. These sections combine the scores of 22 subsections. There is some research support for the reliability of the DIB-R. 24 
Barratt impulSiveneSS Scale
The BIS-11 25 is a self-report measure of impulsivity consisting of 30 statements of personal characteristics. Respondents indicate the extent to which each statement applies using a 4-point scale. The raw impulsiveness measure is the sum of these responses (the larger the sum, the more impulsive is the participant). The scale can be broken into 3 subscales: motor impulsiveness (related to perseverance and unplanned action), non-planning impulsiveness (related to careful consideration of choices and problems), and attentional impulsiveness (related to focus and thought control). sleep characteristics. MANOVAs were computed to compare all 4 groups on the sleep diary data. Bonferroni post hoc analyses were used when needed. Then, because of the peculiar hypotheses related to variability in sleep patterns and the diagnosis of Paradoxical insomnia sufferers, Night 1 to Night 3 were treated independently. As such, paired sample t-tests were used to compare objective and subjective measures of sleep on each night (Night 1 to Night 3) for each group of participants. Finally, repeated measures ANOVAs were performed with within-subject factor (time, 3 levels) and one between-subject independent variable (group, 4 levels) on subjective and objective sleep data. When the sphericity condition was violated, a Greenhouse-Geisser correction to degrees of freedom was applied. To investigate significant interactions, simple effects tests were completed. Significance levels were set at 0.05.
ReSULtS characteristics of Participants
The characteristics of participants are depicted in Table 1 . Statistical analyses showed that GS, BPD-I, Psy-I, and Para-I were similar according to gender, χ 2 (3, N = 57) = 7.228, p = 0.07, and age, F 3,53 = 2.01, p = 0.12.
Both groups of INS and BPD-I, compared to GS, had higher scores on the ISI, F 3,51 = 39.37, p < 0.001, this higher score being indicative of greater severity of insomnia symptoms. As such, BPD-I and both groups of insomnia sufferers reported similar severity of sleep difficulties. Also, both groups of INS and BPD-I expressed more depressive and anxious symptoms than GS as reported on the BDI, F 3,51 = 11.91, p <0.001, and BAI, F 3,51 = 6.57, p <0.001. Although, all participants remained under the clinical threshold for psychiatric syndrome, BPD-I displayed more depressive symptoms than the 3 other groups (mean difference 15.8, 11.8, and 11.1, [p < 0.001] for GS, Psy-I, and Para-I) and more anxious symptoms than GS and Psy-I (mean difference 11.9 and 7.7, respectively).
Compared to GS, the other 3 groups of participants (BPD-I, Psy-I, and Para-I ) reported lower SE, F 3,45 = 20.8, p < 0.001, longer TWT, F 3,45 = 19.4, p < 0.001, and shorter TST, F 3,45 = 12.1, p < 0.001, on the 2 weeks of sleep diaries preceding the laboratory recordings. In addition, Psy-I reported shorter TWT and better SE than Para-I (p < 0.028 and p < 0.025, respectively). BPD-I were comparable on all measures to both Psy-I and Para-I groups. All groups were similar on TIB.
In addition, after completion of the clinical interview, a mean duration of insomnia of 9.3 years (SD = 8.7) was reported by BPD-I. This duration was similar to the ones reported by Psy-I and Para-I. Along with other clinical reports and characteristics previously reported, it thus appeared that BPD-I suffered from chronic insomnia. Table 2 shows results from independent t-tests for 15 pairs of comparisons between sleep measures of objective (PSG) and subjective sleep measures (sleep diary questionnaire in the temperament and character inventory The TCI 26,27 is a 238-item, self-administered, true-false questionnaire developed to assess 7 dimensions of personality. It includes 4 basic dimensions of temperament: 1) novelty seeking; 2) harm avoidance; 3) reward dependence; and 4) persistence. Three dimensions of character are measured: self-directedness, cooperativeness, and self-transcendence.
comparisons Between objective and Subjective Sleep Measures
The TCI as well as the DIB-R and BIS-11 were used explicitly to either confirm or characterize borderline personality disorder participants, and no scores from these scales are reported and/or correlated with subjective or objective sleep in the present study.
Polysomnographic (PSg) Recordings
Participants spent 3 consecutive nights in the sleep laboratory. Participants were instructed to arrive at the sleep laboratory at 20:00 each night for electrode montage and preparation. Participants were asked to refrain from alcohol, excessive caffeine, and nicotine before coming to the laboratory. Bedtime was determined according to reported bedtime on the sleep diary. For all participants, lights-out was initiated after biocalibration. Time in bed was determined according to usual time in bed of participants from the sleep diary, with ≥ 8 hours of PSG recordings.
A standard PSG montage was used, including electroencephalographic (EEG; including C 3 , C 4 , O 1 , O 2 , F z , C z , P z ), electromyographic (EMG; chin) and electro-oculographic (EOG; left and right: supraorbital ridge of one eye and the infraorbital ridge of the other) recordings. This placement allowed for eye movement artifact and blinks to be subtracted from ongoing EEG. 28 Electrodes were referred to linked mastoids with a forehead ground, and interelectrode impedance was maintained <5 kOhms. Respiration and tibialis EMG were monitored during the first night of PSG recording in order to rule out sleep apnea and periodic limb movements. Participants diagnosed with another sleep disorder were excluded and referred to appropriate sleep specialists. A Grass Model 15A54 amplifier system (Astro-Med Inc., West Warwick, RI, USA; gain 10000; band pass 0.3-100 Hz) was used. PSG signals were digitized at a sampling rate of 512 Hz using a commercial software product (Harmonie, Stellate System, Montreal, Canada). Sleep recordings were scored visually (Luna, Stellate System, Montreal, Canada) by qualified technicians according to standard criteria 29 using 20-sec epochs. Reliability checks were conducted by an independent scorer to insure a minimum of 85% interscorer agreement. In addition to being the screening night for sleep disorders other than insomnia, Night 1 constituted an adaptation night. Clinical sleep data measures were derived from Night 2 and 3.
Objective measures of sleep included SOL (defined as the moment from lights off with the intention to sleep to the first consecutive minute of stage 2), WASO, TST, sleep efficiency (%; total sleep time/total recording time), time and proportion (%) of stage 2, 3, 4 and REM, and latency to REM sleep.
Statistical Analyses
First, one-way ANOVAs and chi-square were computed to compare groups on sociodemographic, psychological and
Between-groups and night effects on Subjective and objective Measures of Sleep
Clinical objective data (SE, SOL, number of awakenings, WASO, and TST) are depicted in Table 2 . Table 3 reports on other PSG data for all groups of participants. Repeated measures ANOVAs revealed significant differences on both subjective and objective data. Significant effects (F and p values) can be found in Table 4 .
SuBjective data
BPD-I and GS subjective reports in the sleep laboratory were similar on the 3 recording nights. On the other hand, Psy-I and Para-I subjectively took longer to fall asleep, were awake longer after sleep onset and during the night, slept less, and had a lower SE than both GS and BPD-I (p <0.05). Furthermore, Para-I reported more total wake time, less sleep time, and a lower sleep efficiency than Psy-I (p <0.05). No other significant differences were observed for subjective data.
oBjective data
On objective measures, BPD-I, Psy-I, and Para-I had longer SOL, shorter sleep time and lower sleep efficiency on all 3 nights than GS (p < 0.05). Psy-I took longer to fall asleep, slept less, and had a significantly lower sleep efficiency than GS. Finally, BPD-I had more stage 4 (both in proportion and time) than Para-I on all 3 nights (p < 0.05). No other significant differences were observed for objective measures of sleep.
niGht-to-niGht compariSonS
From Night 1 to Night 3, significant differences were observed for SOL, objective SE, and percentage and minutes of Stage 4 sleep (p < 0.05). Generally, all participants reported and also objectively took less time to fall asleep from Night 1 to the morning) for laboratory nights 1, 2, and 3 for each group of participants. As depicted in Table 2 , within groups differences revealed that BPD-I was the group for whom objective and subjective sleep measures on the 3 nights were the most similar (14 of 15 comparisons), while Para-I was the group of participants whose comparisons between objective and subjective sleep measures differed the most (14 of 15 comparisons). Psy-I differed in their estimation 47% of times, while GS differed 27% of the times.
BPD-I subjective measures from the sleep laboratory were similar to those observed polysomnographically, except for the number of awakenings on the second night. In Para-I, marked discrepancies were observed between subjective and objective reports; only WASO on the adaptation night was correctly estimated. Psy-I consistently underestimated the number of awakenings and overestimated WASO on all 3 nights, although this latter difference was less important than the one found in Para-I. For GS, differences in subjective and objective sleep characteristics were observed almost exclusively on the third night.
An additional subjective measure aimed at comparing sleep in the laboratory to the usual sleep at home labelled "quality of sleep in the sleep lab vs quality of sleep at home" was computed on each night. Quality of sleep was scored on a 5-point Likert scale, from 1 to 5 (1 = much worse; 2 = worse, 3 = same; 4 = better; 5 = much better). GS estimated having slept worse in the laboratory than at home (means = 2.3, 2.5, and 2.7 from the first to the third night, respectively), both Psy-I and Para-I evaluated the quality of the 3 nights in the laboratory as being similar to their sleep at home (2.8, 3.0, and 2.9 for Psy-I and 2.7, 3.0, and 2.9 for Para-I on the 3 nights, respectively). On the other hand, BPD-I rated their sleep in the laboratory as being a bit better than the one at home (from 3.3, 3.4, and 3.3 respectively for each night). ANOVAs revealed that these individuals reported feeling significantly less restored upon awakening (p < 0.001) than any other groups of individuals. compared to other sleepers, these individuals nevertheless reported that their sleep was less refreshing and restorative than the other 3 groups of sleepers. Many studies on insomnia have previously failed to detect or confirm sleep difficulties/complaints in laboratory settings; some studies have found that as many as 50% of patients suffering of chronic primary insomnia do not show objective evidence of insomnia when sleeping in the laboratory environment. [30] [31] [32] [33] Some earlier studies 34, 35 suggested that high inter-night variability may preclude an adequate circumspection of complaints if only one or two nights of PSG are evaluated. However, it was not the case in the present study. Complaints of both groups of primary chronic insomnia sufferers, according to their respective diagnosis, were confirmed by PSG measures (SOL and WASO >30 min), even though inaccurate perceptions of sleep difficulties were observed in these two groups. Again, these results suggest that both groups of primary chronic insomnia sufferers were well diagnosed and categorized according to the criteria of Edinger et al. 13 The picture is less clear for BPD-I. Although subjective reports on sleep diaries and high scores on the ISI along with the clinical interview confirmed that these individuals suffered from chronic insomnia, subjective in-laboratory sleep patterns were not confirmed by objective sleep measures [although WASO was close to the arbitrary cut-off usual for maintenance insomnia (see Table 2 , Night 1 and 2]. A recent study by Philipsen et al.
2 also observed few differences between objective and subjective sleep patterns in BPD-I compared to controls. As mentioned earlier, in regard to insomnia, it has been previously observed that objective sleep patterns do not always reflect the subjective complaint. 33, 34 Furthermore, a PSG evaluation, although characterized as a gold standard, is not recommended for the diagnosis of insomnia. 36 One might also argue that ambulatory recordings No other between night differences reached significance.
DiScUSSion
This research was first aimed at studying the sleep characteristics of BPD-I. Based on clinical observations, it was hypothesized that BPD-I would subjectively share more common characteristics with both groups of insomnia sufferers than with good sleepers. The 2 weeks of sleep diaries completed before laboratory recordings showed that sleep variables of BPD-I, Para-I, and Psy-I were similar but different from GS. Our results suggest that BPD-I suffer from chronic insomnia. Although nightmare occurrences are not available in the current study, these individuals reported sleep difficulties not linked to nightmares as confirmed during the IDI.
20 Para-I were the group of individuals who showed the most important discrepancies between subjective estimates of sleep and objective sleep parameters, which is the group definition criterion. Unexpectedly, BPD-I showed the best concordance between subjective and objective sleep data. Since BPD-I showed no discrepancies between objective and subjective measures of sleep, they were closer in their estimations to good sleepers than to both groups of insomnia sufferers. Nonetheless, objective data from PSG recordings underline longer sleep onset, less total sleep time and lower sleep efficiency in both groups of insomnia and BPD-I compared to GS. Thus, BPD-I do not appear to show common features with Para-I insomnia sufferers more than with other groups of sleepers when studied in the sleep laboratory. Even though BPD-I spent more time in stage 4 sleep than Para-I and reported having slept better in the sleep laboratory than at home 
Borderline Personality and Insomnia
Besides an increase in stage 4 sleep for BPD-I, we did not find any other significant results for this group of individuals. Even if BPD-I displayed a greater score on the depression inventory, no indication of depression-like symptoms linked to clinical sleep measures were observed in the present study. Hence, no shortened REM latency was observed in our sample. These results are in contrast with previous studies. As mentioned earlier, even when concomitant depression was controlled for, shortened REM latency 3, 4 and greater REM density 3,5 was observed in BPD-I compared to controls. It was thus suggested that BPD-I shared common sleep and biological features with severe depression sufferers. Our sample of BPD-I, even with severe complaints and marked distress regarding sleep difficulties and with high scores on the BDI, was very "clean." In that regard, BPD-I were drug-free and did not present any severe psychopathologies. Consequently, our sample of individuals might not have been representative of the severity of clinical symptoms and drug intake in previous studies. It is possible that not being that severely "disordered" precludes these depression-like sleep clinical indices.
It is also possible that PSG alone, although the gold standard in sleep research, is not sensitive enough to circumscribe the nature of the sleep complaints in BPD-I. As mentioned earlier, not all insomnia sufferers' complaints are corroborated with PSG. In that regard, the quantitative analyses of the EEG with PSA, have shown that individuals with psychophysiological insomnia display greater activity in fast-frequency EEG activity bands, notably in the β range 38, 39 than good sleeper controls. Although few data have been reported with Para-I, these individuals appear to display even greater absolute activity in fast-frequency bands than Psy-I. 40 The increased activity in fast-frequency bands might be reflective of a hyperarousal state in those with insomnia. 41 In BPD-I, compared with controls, Philipsen et al. 2 recently showed an increase in δ power in total NREM sleep and across all NREM cycles. Unfortunately, PSA was not applied in the present study. Although an increase in stage 4 sleep might not necessarily reflect an increase in δ power, applying PSA to our sleepers' EEG might concur with the data of Philipsen et al. Furthermore, applying PSA to our (home PSG) may have been more sensitive to the severity of the sleep disturbances in BPD-I. In that regard, Battaglia et al. 10 have indeed observed that the sleep of BPD-I significantly differ from that of controls when sleep was recorded at home. These authors reported longer sleep onset latency and time awake after sleep onset, a greater number of awakenings, a reduced sleep efficiency and proportion of stage 1 sleep as well as a shorter REM latency in BPD-I compared to controls. A comparison of at-home recordings with in-laboratory recordings between our 3 groups of insomnia sufferers might confirm that indeed sleep patterns of BPD-I resemble those of either Para-I and Psy-I when recordings are conducted in natural settings (i.e., home).
As BPD-I are very sensitive to loneliness and interpersonal stressors, laboratory settings might provide a secure context facilitating sleep, and not be representative of "home" sleep. Although sleep at home might be more sensitive to sleep disturbances, it is doubtful that the most striking significant difference we observed in the present study, increased stage 4 (proportion and time) in BPD-I, would be the result of only the laboratory settings. Usually, a greater number of awakenings, more stage shifts, and an increase in lighter stages of sleep are indexes of a lesser quality of sleep. As such, a greater percentage of stage 2 sleep, as observed by Philipsen et al., 2 might, to some limits, have been translated in subjective reports of "bad sleep" by BPD-I. In contrast, our result of increased stage 4 sleep in this group of individuals appears incongruous with their reports of having nonrefreshing and nonrestorative sleep, as well as feeling fatigued upon awakening. It is possible that once a certain amount of time is spent in stage 4, or beyond a certain threshold, the adverse feeling is observed. Thus, nonrestorative sleep could be linked to a greater percentage of stage 4 in BPD-I than in Para-I, despite the observation that the amount of combined stages 3 and 4 remained within reported norms for age and gender 37 in all groups. On the other hand, it is also possible that for BPD-I, feeling nonrestored and nonrefreshed in the morning, despite the high percentage of stage 4 sleep, might simply be part of their general constellation of symptoms or be reflective of another cognitive distortion, like those associated with the personality disorder diagnosis. a lack of significant observed PSG/EEG differences between these individuals and other insomnia sufferers even though they report significant sleep complaints. It is now well recognized that there is a spectrum of severity of BPD symptoms. It is thus possible that more pronounced borderline symptoms are associated with more severe objective sleep difficulties. Finally, hypotheses linked to our statistical design provided numerous within-groups as well as between-groups comparisons with an α set at 0.05. This might lead to some statistical limits. Noneset at 0.05. This might lead to some statistical limits. Nonetheless, considering that many comparisons were also significant at the 0.01 and 0.001 level, we remain confident with the interpretation of our results.
Future studies with larger samples should aim at targeting different ends of continuums to better represent the general population. Furthermore, a study comparing medicated and unmedicated BPD-I could also provide information on sleep perception. In that regard, it is has long been observed that medication, especially benzodiazepines, modifies the perception of sleep in insomnia sufferers. These individuals report being awake less often than being asleep once awakened after a sleep spindle, 42 while the opposite is most often observed with drug-free individuals. Future research should also aim at comparing the microstructure of sleep between groups. These comparisons might help understanding why BPD-I report nonrestorative sleep while displaying an increased amount of stage 4. Finally, the hypothesis of sleep pressure has been put forward for insomnia sufferers, and this interesting question remains to be answered. current data might delineate more subtle differences between BPD-I suffering from chronic insomnia and other groups of primary chronic insomnia sufferers.
Despite these interesting results, the present study has some limits. First, the sample was quite small. It is possible that increasing sample size might have provided clearer differences between Para-I and BPD-I. Increasing sample size might have also increased heterogeneity in the sample of BPD-I. Second, it is possible that our sample of BPD-I was not "severe" enough to display true/marked EEG/PSG difficulties in the sleep laboratory. The recruitment of BPD-I through advertisements might have targeted only individuals displaying the less severe spectrum of the disease. In turn, this might also explain why depression-like sleep abnormalities were not found in the present study compared with many previous ones (which may have included inpatients). Cognitive processes, mood and information processing, although altered, might not have been as severe as those seen in medicated BPD-I. This in turn might translate in 
